LKT Labs

Biochemicals for Life Science Research

AZD-8055

Product ID A9914
Cas No. 1009298-09-2
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $69.00 In stock
25 mg $222.30 In stock
50 mg $344.40 In stock
Bulk Quote

Quicklinks

Description

AZD-8055 is an ATP-competitive mTORC1/2 inhibitor that exhibits immunosuppressive and anticancer chemotherapeutic activities. AZD-8055 promotes antibody class switching in B cells at low doses and decreases B cell proliferation and differentiation at high doses. In vivo, this compound suppresses CC4+ and CD8+ T cell proliferation, increasing survival among MHC-mismatched heart transplant recipients. In vitro, AZD-8055 decreases viability of brain tumor cells; in vivo, it inhibits tumor growth.

Product Info

Cas No.

1009298-09-2
Purity

≥98%
Formula

C25H31N5O4
Formula Wt.

465.55
Synonym

AZD-8055
Solubility

DMSO 50 mg/mL warmed (107.4 mM) Ethanol 3 mg/mL (6.44 mM) Water Insoluble
Appearance

Yellow powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

A9914 MSDS PDF
Info Sheet

A9914 Info Sheet PDF

References

Limon JJ, So L, Jellbauer S, et al. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):E5076-85. PMID: 25385646.

Luchman HA, Stechishin OD, Nguyen SA, et al. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Clin Cancer Res. 2014 Nov 15;20(22):5756-67. PMID: 25316808.

Rosborough BR, Raïch-Regué D, Liu Q, et al. Adenosine triphosphate-competitive mTOR inhibitors: a new class of immunosuppressive agents that inhibit allograft rejection. Am J Transplant. 2014 Sep;14(9):2173-80. PMID: 25307040.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.